PG-116800
Grundinformationen
- CAS
291533-11-4- Standard-SMILES
COc1ccc(C(=O)Nc2ccc(S(=O)(=O)NC(CC#CCN3CCOCC3)C(=O)O)cc2)cc1- InChIKey
JAYVKNDQKXUNOJ-UHFFFAOYSA-N- Summenformel
- C24H27N3O7S
- Durchschnittliche Molmasse
- 501,6 g/mol
- Monoisotopische Masse
- 501,15697138
Überblick
PG-530742 selectively inhibits certain matrix metalloproteinases that have been implicated in the cartilage degradation that occurs in osteoarthritis. By inhibiting these MMPs, it potentially limits cartilage degradation and disease progression. Studies are currently assessing the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.
Namen und Bezeichner
- Bevorzugter Name
- PG-116800
- IUPAC
- 2-[[4-[(4-methoxybenzoyl)amino]phenyl]sulfonylamino]-6-morpholin-4-ylhex-4-ynoic acid
- Englischer Name
- PG 116800
- Summenformel
- C24H27N3O7S
- Molmasse
- 501.55208
Namen und Synonyme
291533-11-4PG-116800F94T42GL80PG-5307424-Hexynoic acid, 2-(((4-((4-methoxybenzoyl)amino)phenyl)sulfonyl)amino)-6-(4-morpholinyl)-PGE7113313PGE-71133134-Hexynoic acid, 2-[[[4-[(4-methoxybenzoyl)amino]phenyl]sulfonyl]amino]-6-(4-morpholinyl)-RefChem:172346PG 116800PG-530742 free acidUNII-F94T42GL80
Weitere Namen anzeigen
PG 116800,PG116800JAYVKNDQKXUNOJ-UHFFFAOYSA-N
PGE 530742PGE 7113313PG 5307422-[[4-[(4-methoxybenzoyl)amino]phenyl]sulfonylamino]-6-morpholin-4-ylhex-4-ynoic acidPG 530742; PGE 530742; PGE 7113313PG-116800 Sodium SaltPG-530742 SODIUMorb1699640
Datenbank-Bezeichner
- CAS
291533-11-4- PubChem CID
- 9848869
- ChEMBL
CHEMBL4297318- UNII
- F94T42GL80
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- -0,8
- Polarare Oberfläche (TPSA)
- 143 Ų
- H-Brücken-Donoren
- 3
- H-Brücken-Akzeptoren
- 9
- Frei drehbare Bindungen
- 9
- Schwere Atome
- 35
- Formalladung
- 0
- Komplexität
- 870
Physikochemische Eigenschaften
- Aggregatzustand
- Solid
- Farbe
- White to off-white
Chemie und Industrie
Pharmakologische Informationen
Pharmacodynamics
PG-530742 selectively inhibits certain matrix metalloproteinases that have been implicated in the cartilage degradation that occurs in osteoarthritis. By inhibiting these MMPs, it potentially limits cartilage degradation and disease progression. Studies are currently assessing the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.
Mechanism of ActionPG-530742 selectively inhibits certain matrix metalloproteinases: In an independent research study, the drug-treated group showed decreased levels of MMP-2, -3, -9, and -13.
Anbieter5 Anbieter
北京博奥森生物技术有限公司400-901-9800 18611424007 · [email protected]
上海陶术生物科技股份有限公司+1-781-999-5354; +1-00000000000 · [email protected]
上海一飞生物科技有限公司021-65675885 18964387627 · [email protected]
TargetMol中国（陶术生物）15002134094 · [email protected]
上海阿摩尔生物科技有限公司13370042665 18916960931 · [email protected]
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…